Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Department of Endoscopy, Nagoya University Hospital, Nagoya, Japan.
J Gastroenterol Hepatol. 2018 Jan;33(1):320-328. doi: 10.1111/jgh.13967.
The aim of this study is to elucidate the natural history of pancreatic cystic lesions (PCLs), including branch duct-type intraductal papillary mucinous neoplasm (BD-IPMN), via midterm follow-up analysis of a multicenter prospective observational study (NSPINAL study).
From July 2011 to October 2016, 881 patients with PCLs were enrolled in NSPINAL study, and 664 patients with > 12 months of follow up were analyzed. Every patient was asymptomatic, and endoscopic ultrasound was performed at the initial diagnosis to exclude high-risk individuals. Follow up included endoscopic ultrasound, computed tomography, or magnetic resonance imaging at least once a year. Serial morphological changes and the pancreatic cancer (PC) incidence, including malignant progression of PCLs, were evaluated.
The 664 patients (358 men) were followed for a median of 33.5 months (interquartile range 29). The cyst and main pancreatic duct sizes were 16.6 ± 9.3 and 2.3 ± 1.0 mm, respectively. Morphologically, 518 cases were multilocular, 137 were unilocular, and 9 had a honeycomb pattern; 269 cases involved multifocal lesions. Ninety-six patients (14.5%) showed worsening progression on imaging. There were two resectable and four unresectable cases of pancreatic ductal adenocarcinoma and three cases of malignant BD-IPMN. The 3-year risk of developing PC was 1.2%. The standardized incidence ratio for PC among PCLs was 10.0 (95% confidence interval 3.5-16.5), and the standardized incidence ratio among BD-IPMN was 16.6 (95% confidence interval 5.1-28.1). Multivariate analysis showed that development of symptoms and worsening progression were significant predictors of PC.
Malignant progression of PCLs, including PC development, is not uncommon. Patients with PCLs should be carefully monitored to detect pancreatic ductal adenocarcinoma at early stages.
本研究旨在通过对一项多中心前瞻性观察研究(NSPINAL 研究)的中期随访分析,阐明胰腺囊性病变(PCL)的自然史,包括分支胰管型胰管内乳头状黏液性肿瘤(BD-IPMN)。
2011 年 7 月至 2016 年 10 月,NSPINAL 研究纳入 881 例 PCL 患者,其中 664 例随访时间>12 个月。所有患者均无症状,初始诊断时行内镜超声检查排除高危人群。随访包括每年至少一次内镜超声、计算机断层扫描或磁共振成像。评估连续形态变化和胰腺癌(PC)的发生率,包括 PCL 的恶性进展。
664 例患者(358 例男性)中位随访时间 33.5 个月(四分位距 29)。囊肿和主胰管直径分别为 16.6±9.3mm 和 2.3±1.0mm。形态上,518 例为多房性,137 例为单房性,9 例为蜂窝状;269 例为多灶性病变。96 例(14.5%)影像学表现为进展性加重。有 2 例可切除和 4 例不可切除的胰腺导管腺癌及 3 例恶性 BD-IPMN。3 年 PC 发病风险为 1.2%。PCL 中 PC 的标准化发病比为 10.0(95%置信区间 3.5-16.5),BD-IPMN 为 16.6(95%置信区间 5.1-28.1)。多变量分析显示,症状出现和进展性加重是 PC 的显著预测因素。
PCL 的恶性进展,包括 PC 的发生并不少见。应仔细监测 PCL 患者,以早期发现胰腺导管腺癌。